business
U.S. opens tariff probe targeting Germany’s drug pricing policies
Key takeaways
- Livestream Menu Make Itselect USAINTLLivestream Search quotes, news & videos Livestream Watchlist SIGN INCreate free account Markets Business Investing Tech Politics Video Watchlist Investing Club PROLivestream Menu
- "President Trump has made clear that American patients should not be shouldering a disproportionate share of global pharmaceutical research and development," said U.S.
- "I am particularly concerned with news that Germany is fast-tracking legislation that would further reduce its spending on innovative pharmaceuticals," he said, calling it "a serious step backwards."
Livestream Menu Make Itselect USAINTLLivestream Search quotes, news & videos Livestream Watchlist SIGN INCreate free account Markets Business Investing Tech Politics Video Watchlist Investing Club PROLivestream Menu
The U.S. has launched an investigation into Germany's pharma policies over what it referred to as "persistent underpayment" for medicines as the European country looks to limit spiraling healthcare costs, including spending on drugs.
"President Trump has made clear that American patients should not be shouldering a disproportionate share of global pharmaceutical research and development," said U.S. Trade Representative Jamieson Greer in a statement late Thursday.
Article preview — originally published by CNBC. Full story at the source.
Read full story on CNBC →
More top stories
Also covered by
Investing.com
US launches Section 301 probe into Germany over drug pricing
Investing.com
US launches trade investigation into Germany over drug pricing
France 24
US launches Germany pharma pricing probe, raising threat of new tariffs
Bloomberg Markets
US Starts Section 301 Probe of Germany Over Pharmaceuticals
Aggregated and edited by the Scoop newsroom. We surface news from CNBC alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop